{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:35:14Z","timestamp":1772552114734,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ygyno.2024.07.682","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T17:09:36Z","timestamp":1725383376000},"page":"209-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus"],"prefix":"10.1016","volume":"190","author":[{"given":"B.","family":"Pothuri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Sawaged","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.C.","family":"Karpel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Musa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Reese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.V.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.R.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.D.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.M.","family":"Muggia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.07.682_bb0005","series-title":"Facts and Figures","author":"Society, A.C","year":"2016"},{"issue":"4","key":"10.1016\/j.ygyno.2024.07.682_bb0010","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jnci\/djx214","article-title":"International patterns and trends in endometrial cancer incidence, 1978-2013","volume":"110","author":"Lortet-Tieulent","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.ygyno.2024.07.682_bb0015","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ygyno.2012.03.034","article-title":"Late-breaking abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A gynecologic oncology group study","volume":"125","author":"Miller","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.07.682_bb0020","series-title":"NCCN Clincal Practice Guidelines in Oncology: Uterine Neoplasms. Version 1","year":"2022"},{"issue":"5","key":"10.1016\/j.ygyno.2024.07.682_bb0025","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00280-018-3559-y","article-title":"Carboplatin (every 21 days) and divided-dose paclitaxel (days 1, 11): rationale and tolerance in chemotherapy na\u00efve women with high-grade epithelial cancers of Mullerian origin","volume":"81","author":"Kudlowitz","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"6","key":"10.1016\/j.ygyno.2024.07.682_bb0030","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/IGC.0b013e3181ad3dcb","article-title":"Leuven dose-dense paclitaxel\/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma","volume":"19","author":"Vandenput","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"25","key":"10.1016\/j.ygyno.2024.07.682_bb0035","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1200\/JCO.2005.11.013","article-title":"Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer","volume":"23","author":"Ibrahim","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.07.682_bb0040","unstructured":"Brochure, I.s., ABRAXANE\u00ae (Paclitaxel Albumin Nanoparticle for Injectable Suspension) (ABI-007), I. American BioScience, Editor."},{"issue":"17","key":"10.1016\/j.ygyno.2024.07.682_bb0045","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non\u2013small-cell lung cancer: final results of a phase III trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.07.682_bb0050","series-title":"Abraxane (Paclitaxel Protein-Bound Particles for Injectable Suspension) (albumin bound) [prescribing information]","year":"2013"},{"key":"10.1016\/j.ygyno.2024.07.682_bb0055","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.07.682_bb0060","unstructured":"US Food and Drug Administration. Drugs: paclitaxel. Updated September 9, 2013. www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm367613.htm. Accessed December 21, 2022."},{"key":"10.1016\/j.ygyno.2024.07.682_bb0065","first-page":"1","article-title":"Adjuvant carboplatin and paclitaxel chemotherapy followed by radiotherapy in high-risk endometrial cancer: A retrospective analysis","volume":"4","author":"Bonadio, R.R.d.C.C","year":"2018","journal-title":"J. Global Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.07.682_bb0070","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ygyno.2006.03.019","article-title":"Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: A retrospective study","volume":"103","author":"Sovak","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.07.682_bb0075","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2021.32.e64","article-title":"A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial","volume":"32","author":"Hori","year":"2021","journal-title":"J. Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2024.07.682_bb0080","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/cas.15310","article-title":"Adjuvant chemotherapy for endometrial cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma","volume":"113","author":"Egawa-Takata","year":"2022","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.ygyno.2024.07.682_bb0085","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/IGC.0b013e31824a3385","article-title":"Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma","volume":"22","author":"Vandenput","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2024.07.682_bb0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10147-006-0619-9","article-title":"Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer","volume":"12","author":"Secord","year":"2007","journal-title":"Int. J. Clin. Oncol."},{"issue":"6B","key":"10.1016\/j.ygyno.2024.07.682_bb0095","first-page":"3971","article-title":"Weekly low-dose paclitaxel and carboplatin therapy in gynecological cancer patients with venous thrombosis","volume":"28","author":"Tabata","year":"2008","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2024.07.682_bb0100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ygyno.2010.10.025","article-title":"A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer: a Kansai clinical oncology group study (KCOG0015 trial)","volume":"120","author":"Ito","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.07.682_bb0105","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/onco.13680","article-title":"Reconsidering dexamethasone for antiemesis when combining chemotherapy and immunotherapy","volume":"26","author":"Janowitz","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2024.07.682_bb0110","unstructured":"FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-endometrial-cancer-indication-dostarlimab-gxly-chemotherapy#:~:text=On%20August%201%2C%202024%2C%20the,recurrent%20endometrial%20cancer%20(EC). Accessed on June 20, 2024."},{"issue":"2","key":"10.1016\/j.ygyno.2024.07.682_bb0115","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ygyno.2008.01.028","article-title":"Carboplatin and paclitaxel in advanced or metastatic endometrial cancer","volume":"109","author":"Pectasides","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"33","key":"10.1016\/j.ygyno.2024.07.682_bb0120","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.07.682_bb0125","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ygyno.2017.07.134","article-title":"Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer","volume":"147","author":"Kogan","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.07.682_bb0130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ygyno.2011.06.027","article-title":"Racial disparities in histopathologic characteristics of uterine cancer are present in older, not younger blacks in an equal-access environment","volume":"123","author":"Oliver","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.07.682_bb0135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ygyno.2021.07.022","article-title":"Racial disparities in survival among women with endometrial cancer in an equal access system","volume":"163","author":"Park","year":"2021","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824010461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824010461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T02:05:43Z","timestamp":1730945143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824010461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":27,"alternative-id":["S0090825824010461"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.07.682","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.07.682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}